Classys FY 2025 Annual ReportBeta
Classys annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Classys FY 2025 Annual Report Analysis
Business Overview
- • Medical aesthetic device sales KRW 328.5B (97.5% of total KRW 336.8B) in FY2025 with consumables as a key revenue category
- • Acquisition of JL Health Participacoes S.A. in Brazil completed on March 5, 2026, via 100% subsidiary Classys Brasil Ltda.
Management Discussion & Analysis
- • Revenue KRW 336.8B (+38.6% YoY), Operating Profit KRW 170.6B (+39.3%), Net Income KRW 132.0B (+35.3%) in FY2025, record high
- • Equipment segment revenue increased by KRW 49.7B (40.0%) driven by ULTRAFORMER MPT and VOLNEWMER brand recognition and new products from Iruda merger
Risk Factors
- • No derivative financial instruments held or liabilities as of fiscal year 2025
- • New put and call option contracts signed between Classys Brasil Ltda. and JL Health Participacoes S.A. completed March 5, 2026
Classys FY 2025 Key Financial MetricsDART
Total Assets
KRW 704.6B
▲ +15.8% YoY
Operating Cash Flow
KRW 163.9B
▲ +59.5% YoY
CapEx
KRW 12.9B
▲ +215.8% YoY
Source: KIFRS consolidated financial data from Classys annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding